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guidelines and provide a practical means for the different 
disciplines that treat this complex disease.
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Prologue
Gastrointestinal stromal tumors (GIST) are the most com-
mon mesenchymal tumors originating in the digestive 
tract. They have a characteristic morphology, are gener-
ally positive for CD117 (c-kit) and are primarily caused by 
activating mutations in the KIT or PDGFRA [1]. On rare 
occasions, they occur in extravisceral locations such as the 
omentum, mesentery, pelvis and retroperitoneum.
GIST have become a model of multidisciplinary work in 
oncology: the participation of several specialities (oncolo-
gists, pathologists, surgeons, molecular biologists, radi-
ologists…) has allowed advances in the understanding 
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of this tumor and the consolidation of a targeted therapy, 
imatinib, as the first molecular treatment that is effective 
in solid tumors. Following the introduction of this drug, 
median survival of patients with advanced stage GIST has 
increased from 18 to more than 60 months. Additionally, 
sunitinib is another targeted drug registered as second-line 
treatment for metastatic GIST.
Diagnosis
Radiology
Radiological diagnosis of GIST is similar to that of other 
digestive-tract tumors. In barium studies, GIST appear 
as submucosal lesions [2] and in ultrasound studies as 
hypoechogenic masses that, when large, can displace 
neighboring structures and show cystic, necrotic or hemor-
rhagic areas.
A computerized tomography (CT) scan and magnetic 
resonance imaging (MRI) are the first choice to study 
location and extension [3]. A CT with contrast and image 
acquisitions of the arterial and portal phases allows iden-
tification of hypervascular hepatic lesions that would oth-
erwise go unnoticed and become evident when they turn 
hypodense with treatment. The latter could wrongly sug-
gest progression due to the development of new lesions. On 
the contrary, a CT scan without endovenous contrast allows 
detection of a hemorrhage or intratumoral calcification.
In a CT, tumors appear as well-circumscribed exolu-
minal masses that, after the contrast, show heterogeneous 
enhancement, especially large tumors, which may have 
necrotic-hemorrhagic areas or degenerative components 
[4].
An MRI is useful for the local study of tumors located 
in the pelvic area [5] as well as for the study of the mesen-
teric and peritoneal extension. With PET, small GIST have 
a homogeneously increased uptake, while in large lesions 
(>4 cm), uptake may be heterogeneous [6].
Histology
Techniques for histological diagnosis
The technique of choice for providing histological diag-
nosis is echoendoscopy-guided biopsy or a CT-guided 
percutaneous biopsy when the first option is not possible. 
Although FNA (fine-needle aspiration) endoscopy could 
be performed on esophagogastric tumors, this technique 
does not usually provide sufficient material to carry out 
a proper, definitive histological diagnosis, thus a biopsy 
would also be called for. If the biopsy become complex, 
a laparoscopic incision or laparotomy is required in order 
to obtain diagnosis. However, the use of biopsy forceps for 
polypectomy increases the risk of perforation and should 
be avoided and performed in exceptional cases only [7].
Preoperative endoscopic biopsy is not necessary when a 
lesion is considered suspicious, resectable or operable. On 
the other hand, it would be appropriate for patients with 
disseminated disease or in locally advanced cancers when 
considering neoadjuvant therapy [8].
Samples should be fixed in formaldehyde and not in Boi-
un’s solution as it may alter results in subsequent studies.
Pathological characteristics
GIST are the most common mesenchymal tumors origi-
nating in the digestive tract. They have characteristic mor-
phological features and are generally positive for CD117 
(c-kit) and have active KIT o PDGFRA mutations [1].
Macroscopic characteristics Most common sites They are 
usually found in stomach (60 %), small intestine, jejunum 
and ileum (30 %), duodenum (5 %), rectum (2–3 %), colon 
(1–2 %). They are much less frequent in the esophagus 
(<1 %). In some cases, there is presence of disseminated 
tumor with unknown primary tumor and a small number of 
them, and the tumor originates in the omentum, mesentery 
and retroperitoneum [9, 10]. Metastases are typically intra-
abdominal involving the peritoneum and liver; from a dis-
tance, they are odd looking and usually found on skin, bones 
and soft tissue.
Morphology The size of GIST is variable (up to 38 cm). 
Most measure around 5 cm at the time of diagnosis. They 
typically originate in the digestive tract and can be sub-
mucosal, intramural or subserosal. They are rarely inva-
sive and there is often ulceration of the mucous membrane 
with poor prognosis [10]. Necrotic, hemorrhagic and 
cystic degeneration areas are usually displayed [11]. They 
are usually solitary, sporadic cases usually have multiple 
lesions [12] in familial or neurofibromatosis GIST and Car-
ney Triad [13]. Its growth pattern is extensive (21 %) and 
pseudo-extensive (45 %) or infiltrative (24 %). The pathol-
ogy report must always include three-dimensional tumor 
measurement, and the existence of quantification of necro-
sis and distance between lesion and margin as incomplete 
resection is associated with poor prognosis [14].
Microscopic characteristics Three histological types can 
be distinguished according to the cellular appearance: fusi‑
form cells (77 %), epithelioid cells (8 %) and mixed (15 %) 
(1). The epithelial type is more frequently observed in stom-
ach and epiplon [15].
The number of mitosis can vary substantially, between 0 
and over 150 mitoses per 50 high-power fields (hpf). Most 
show a low or very low mitotic index (≤5 mitosis/50 hpf). 
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The method for counting mitoses in the most active areas, 
in a total of 50 hpf (corresponding to an area 10 mm2), 
should be standardized given its prognostic relevance. 
Strict criteria should be followed as pyknosis and karyor-
rhexis must not be overlooked. The mitotic index should be 
graded as follows: low ≤5/50hpf and high >5/50hpf [16].
Immunohistochemistry Over 95 % of GSIT have CD117 
(c-kit) expression with diffuse cytoplasmic staining pattern 
but also rarely in the membrane or Golgi apparatus. There is 
intense staining in 75 % of cases. Moreover, 70–90 % also 
express CD34, 20–30 % actin, 8–10 % S-100 and desmin in 
2–4 % [1]. IHC studies are useful in confirming a diagnosis 
of GIST and given the implications of diagnosis, appropri-
ate CD117 immunohistochemistry in order to avoid errors. 
Staining of Ki67 is a prognostic factor and recommended 
[17]. DOG1 can optionally be included in the initial panel 
and is highly recommended in negative c-kit [18], in which 
DOG1 is expressed in over 35 % of cases.
Differential diagnosis The main differential diagnosis in 
fusiform GIST comprises smooth muscle tumors (leiomyoma 
and leiomyosarcoma); schwannoma and malignant peripheral 
nerve sheath tumor; inflammatory myofibroblastic tumor; 
solitary fibrous tumor, sarcomatoid carcinoma; inflamma-
tory fibroid polyp and desmoid fibromatosis. Differential 
epithelioid GIST diagnosis includes poorly differentiated 
carcinomas; endocrine cancers and variants of epithelioid lei-
omyosarcoma and malignant peripheral nerve sheath tumor. 
Luckily, morphological features together with an adequate 
immunohistochemical panel allow proper diagnosis [11].
Kit‑negative GIST Between 4 and 5 % of GIST with typi-
cal morphological features are negative for CD117 [19, 20]. 
Those with negative stains or weak staining <10 % of tumor 
extension are to be considered as such. Kit-negative GIST 
is clinically, pathologically and genetically different from 
kit-positive GIST. Although they are more frequently found 
in stomach, they can also be observed in the omentum and 
peritoneal surface. They are less commonly CD34 and actin 
positive, while desmin expression is approximately 30 %, 
especially in stomach lesions and epithelioid morphology 
[18]. DOG1 positive was observed in slightly over one-third 
of tumors [18]. Other antibodies such as PCK tetha or PDG-
FRA have been found not to be very reproducible or useful 
[21, 22].
Kit-negative GIST present a true diagnostic challenge. It 
is recommended to extend the immunohistochemical panel 
with other markers such as DOG1 and a mandatory study 
for KIT and PDGFRA mutation, being mindful that there 
is a small percentage of GIST with typical morphology, 
negative for CD117 and DOG1 and wild type for KIT and 
PDGFRA genotype [20]. Cases morphologically defined as 
atypical, cellular atypia, CD117 and DOG1 negative and 
with no KIT or PDGFRA mutations should not be classified 
as GIST.
Final recommendations
•	 Pathologic diagnosis is based on both unique micro-
scopic features and ancillary techniques (CD-117, 
CD34, actin, desmin, S-100 and ki-67), which are very 
important to confirm diagnosis.
•	 The pathology report must include tumor size; number 
of mitoses per 50 HPF (10 mm2) counted in the most 
active regions; and margins status.
•	 It is advisable to refer the complex or unusual cases to 
experienced centers.
•	 Regarding tumors with typical morphology GIST, an 
extended phenotype of DOG1 as well as KIT and PDG‑
FRA gene mutation analysis is required.
•	 Albeit optional, it is convenient to include the risk group 
separated by site. Table 1 (Miettinen et al.) [23] and his-
tologic grading defined exclusively by the number of 
mitosis (low grade ≤5/50HPF, high grade >5/50HPF).
Molecular diagnosis
GIST are characterized by activating mutations in KIT 
and PDGFRA genes—are shown to be mutually exclusive 
encoding a receptor tyrosine kinases type III (RTC) [11, 
12]. KIT mutations are found in 60–85 % of GIST tumors, 
while PDGFRA mutations are found in 5–10 %. Approxi-
mately 10–15 % of GIST do not have detectable mutations 
in any of these receptors (GIST wild type), suggesting that 
other molecular routes can also be involved in the patho-
genesis of these tumors [24–26].
Table 1  Primary gastrointestinal stromal tumors (GIST) risk assess-
ment guidelines
*
  Defined as metastasis or cancer-related death
**
  Small number of cases
***
  See stomach for omentum and other locations (esophagus, colon, 
peritoneum and mesentery) see small bowel
Tumor parameters Risk of progression* (%)
Mitotic index Size Stomach*** Small bowel***
≤5 per 50 high-
power field 
(HPF)
≤2 cm No (0 %) No (0 %)
>2–≤5 cm Very low (1.9 %) Low (4.3 %)
>5–≤10 cm Low (3.6 %) Moderate (24 %)
>10 cm Moderate (10 %) High (52 %)
>5 per 50 HPF ≤2 cm No** High**
>2–≤ 5 cm Moderate (16 %) High (73 %)
>5–≤10 cm High (55 %) High (85 %)
>10 cm High (86 %) High (90 %)
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Spectrum of mutations in GIST
Mutations found in GIST mainly affect exons which cod-
ify functional domains of KIT and PDGFRA receptors. 
Among the main types of mutation, we find the follow-
ing: deletions, point mutations, duplications, insertions and 
complex mutations [19].
Mutation detection before tyrosine kinase (TK) inhibi-
tor therapy such as imatinib is known as primary muta-
tion (and mainly affects exons 11, 9, 13 and 17 of KIT, 
and exons 18, 12 and rarely affects 14 of PDGFRA). 
Meanwhile, mutations detected during treatment, which 
are to a large degree responsible for resistance to TK 
inhibitors, are known as secondary mutations (generally 
detected in exons 13, 14 and 17 of KIT and 18 of PDG-
FRA) [24, 26].
KIT mutations The most common KIT mutations affect 
exon 11 (juxtamembrane domain). Approximately 70 % 
of GIST present some type of mutation in this exon [24, 
27]. The most frequent mutations in this exon are intersti-
tial deletions, commonly affecting the beginning of exon 
11 (between codons 550 and 579) and especially codons 
557–559. Then, there are point mutations, albeit with a 
lower incidence, and limited to four codons (557, 559, 560 
and 576). Lastly, at the extreme end of the exon (between 
codons 571 and 591) and in a much smaller proportion of 
patients, we find tandem duplications associated with GIST 
gastric site and epithelioid or mixed cell morphology [25, 
28–30].
In exon 9 (extracellular domain), only duplication of 
residues 502–503 have been described and is present in 
9–20 % of cases depending on the study. This mutation is 
mainly associated with GIST of small bowel location and 
greater malignant potential [26, 30].
The KIT-TK domains are encoded by exons 13 and 17. 
Only point mutations have been found in these exons, the 
frequency being between 0.8 and 4.1 % for exon 13 lower 
than 1 % in the case of exon 17 [25, 26, 30–32].
PDGFRA mutations Overall, the estimated frequency 
rate of PDGFRA mutations in GIST is 5–10 % [24, 25, 33], 
which are associated with localized gastric GIST and epithe-
lioid morphology [25, 27, 33]. Mutations are concentrated 
in the juxtamembrane domain (0.7 %) encoded by exon 12; 
in TK domain (6 %) encoded by exon 18, DD842 V muta-
tion being the most frequent (65–75 %); and very rarely in 
exon 14 (0.1 %) [24, 25, 27, 33].
GIST wild type Around 12–15 % of adult GIST and 
90 % of pediatric GIST lack KIT and PDGFRA muta-
tions [19]. Molecular pathogenesis and tumor biology 
of this subgroup represent one of the greatest areas of 
speculation and investigation in which the involvement 
of other TK receptors, such as IG1R, has already been 
demonstrated [34]. Besides, other intracellular signaling 
pathways as the one controlled by BRAF, with mutations 
described in 7 % of wild-type GIST [35] and mutations in 
the succinate dehydrogenase enzymatic complex subunit 
genes (SDHC), are mostly associated with germline muta-
tions [36].
Kit‑negative GIST
Approximately 5 % of GIST are c-kit negative, leading 
to diagnostic difficulties. Between 30 and 50 % of these 
tumors present mutations in KIT or PDGFRA [27, 37–39], 
which may have therapeutic implications. The notion that 
a GIST can be negative for c-kit as well as wild type for 
KIT and PDGFRA mutations is not entirely clear consid-
ering that current diagnosis is performed by exclusion 
[27]. Furthermore, the last European consensus proposed, 
using a mutational analysis of KIT and PDGFRA, to con-
firm GIST diagnosis, especially in CD117/DOG1 negative 
cases [40].
Syndromes associated with GIST
At present, there are many syndromes associated with 
GIST, among them:
1. Carney Triad: characterized by gastric GIST, paragan-
glioma, pulmonary chondroma, which may develop in 
any age group, making it difficult to discard this condi-
tion in pediatric wild-type GIST [41].
2. Neurofibromatosis Type 1: usually marked by a wild-
type GIST predominantly located in the small intestine 
and quite possibly a multicenter study [42].
3. Carney–Stratakis syndrome: characterized by germline 
mutations in some subunits of the succinate dehydro-
genase enzyme (SDHB, SDHC y SDHD) producing a 
dyad of GIST and paraganglioma [43, 44].
Final recommendations
The last multidisciplinary ESMO consensus [40] recom-
mends including a molecular systematic analysis in the 
diagnosis of all GIST (specially advanced GIST), given 
the type of relevant predictive and prognostic information 
provided and required in cases of GIST without CD117 
and DOG1 expression. In these cases, it is recommended 
to refer patients to a reference center with their own labo-
ratory, integrated in quality assurance programs and with 
proven experience.
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Predictive factors in locally advanced or metastatic 
disease
Genotype correlation in primary disease with therapeutic 
results with imatinib for first line
Patients with an exon 11 KIT mutation have a better chance 
of responding, a longer time to progression (TTP) overall 
survival (OS) versus those with exon 9 mutations or wild 
type [45–47]. Moreover, the meta-analysis carried out in 
2 phase II trials (EU-AUS and US-CDN) comparing 400 
versus 800 mg of daily imatinib in patients with metastatic 
or non-resectable GIST, showed that patients with exon 11 
mutation had a better progression-free survival (PFS) and 
overall survival with respect to exon 9 mutation or wild 
type [41].
Genotype correlation in primary disease with therapeutic 
results imatinib dosage
In the above-mentioned meta-analysis, it was found that 
mutations in exon 9 were the only predictive factor for 
imatinib response with greater benefit, statistically sig-
nificant for PFS patients who received high doses of 
imatinib. A 31 % lower risk of death was observed in 
favor of 800 mg, although it did not reach statistical dif-
ference [48]. These findings confirm data previously 
disclosed by the European study. Unlike the American 
study, which only had 32 patients with exon 9 mutations, 
the European one showed 58 patients with same muta-
tions [48, 49].
Primary genotype correlation with therapeutic results 
with sunitinib as second-line therapy
Sunitinib inhibits multiple receptor tyrosine kinases 
(VEGFR, PDGFR, KIT, FLT3) and has a higher receptor 
binding affinity than imatinib. Data obtained from Phase 
I/II clinical trials of 78 patients (out of 97) treated with 
sunitinib as second line and with preimatinib genotype 
information showed that patients with exon 9 mutations 
and wild-type tumor were associated with a more favora-
ble outcome (partial response and disease stabilization over 
6 months) compared with those with exon 11 mutations. 
Furthermore, the median PFS was significantly higher 
in patients with primary exon 9 mutation (19.4 months; 
p = 0.0005) or wild type (19 months; p = 0.0356) regard-
ing those with exon 11 mutations (5.1 months). A signifi-
cantly greater OS was obtained, comparing those with exon 
9 mutations, (26.9 months; p = 0.012 and 30.5 months; 
p = 0.0132) for wild type, as opposed to those with exon 11 
mutations (12.3 months) [49].
Secondary genotype correlation with therapeutic results 
for sunitinib
It is acknowledged that secondary resistance observed in 
patients with metastatic GIST is mostly developed due to 
the appearance of secondary mutations. Interestingly, no 
secondary mutations were found in initially wild type and 
resistant patients [50].
In vivo data obtained from biopsies carried out at the 
time of progression to imatinib provide important informa-
tion on secondary mutations identified in 64 % of the avail-
able cases. Significant clinical benefit as well as RFS was 
better in cases with secondary mutations localized in exon 
13 or 14 with regard to those in exon 17 or 18 [12].
Mechanisms of resistance to imatinib
Resistance to imatinib is a major therapeutic problem as, 
among patients who fail to respond to initial imatinib (pri-
mary resistance, 5–15 %) or stop responding (secondary 
resistance), barely 5 % respond to conventional treatments. 
Primary resistance can be defined as that occurring in the 
first months of imatinib therapy. Progression is typically 
multifocal, and mutations are frequently found in exons 
9 and WT. The mechanisms for secondary resistance to 
imatinib are heterogeneous and can be grouped into various 
groups [51, 52]:
•	 Acquisition of secondary KIT mutations
•	 KIT gene amplification
•	 Activation of alternative signaling pathways
•	 Functional resistance due to KIT or PDGFRA activation 
in absence of secondary mutations.
The most common mechanism is the appearance of a 
new mutation. Secondary mutations in exons 13, 14, 17 or 
18 account for 62 % of GIST with primary in KIT exon 
11 mutations but only in 16 % have a primary mutation of 
exon 9. Moreover, no secondary mutations appear in GIST 
which do not have a primary mutation in KIT or PDGFRA 
[49]. There is evidence of clonal and/or polyclonal evolu-
tion of secondary mutations in a small proportion of patients 
(18.8 %). In this way over time, the same patient may 
develop secondary mutations in different tumor resistant 
implants. In view of this finding, the therapeutic approach 
of these patients will have to be taken into account [50, 53].
Final recommendations
The clinical application of secondary mutation findings is 
not so clear-cut at the present time and should be subject to 
further research studies.
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Lastly, given the interest in translational studies regard-
ing this neoplasm, it is advised to take fresh tissue for the 
application of new technologies of molecular pathology, 
which will ultimately have a positive impact on the patient.
Treatment
It is highly advised that diagnostic and therapeutic pro-
cesses could be referred to expert teams for GIST care [54].
Localized disease
Surgery for localized disease
Complete surgical resection is the standard treatment for 
localized GIST. Radiological criteria for unresectability 
include infiltration of the celiac trunk, the superior mesen-
teric artery or mesenteric artery-to-portal vein. Lymphad-
enectomy is unnecessary given the low frequency of lymph 
node metástasis or metastasis. Some exceptions could be 
SDH-deficient GIST especially in pediatric population.
The aim was to achieve a R0-type surgery (optimal sur-
gery), complete removal leaving an intact capsule. It is 
therefore necessary, in some cases, to remove neighboring 
organs and perform a surgical “block excision.” Segmen-
tal resection of intestine and stomach is accepted, and thus, 
aggressive and a more extensive surgery to remove unaf-
fected tissue is unnecessary [55].
Regarding R1 resection (marginal excision containing 
tumor cells), reexcision could be offered and shared with 
the patient, if this does not imply major functional squeals. 
If the context of R1 surgery is a very low- to low-risk 
tumor, the physician should communicate the wait-and-see 
approach to the patient as opposed to aggressive surgery 
with permanent damage since there is no clear evidence 
that R1 margins entail a worse prognostic in such cases.
Peritoneal and hepatic surfaces should be carefully 
examined during a laparotomy to rule out tumor spread. 
Tumor resection must be carefully performed to avoid 
tumor rupture. In this regard, a laparoscopic approach is 
strongly discouraged in patients with voluminous tumors.
Prognostic factors after surgery in localized GIST
Relapse-risk assessment for primary GIST is paramount 
not only providing prognostic information when trying to 
determine risk factors but also estimating the potential ben-
efit of adjuvant imatinib. In 2002, an index was proposed 
(NIH Consensus NIH or Fletcher) [15] based on studies of 
prognostic factors studies for patients with localized GIST, 
to estimate the risk of recurrence (Table 2; Fig. 1), based 
on the number of mitosis per 50 high-power fields (HPF), 
the size of the primary tumor and the two variables with the 
greatest prognostic significance. Principally, it seems that 
any GIST has malignant potential and the index makes it 
possible to classify GIST patients according to risk factors 
and complete resection.
Subsequently, Miettinen et al., analyzed data of 1.765 
patients with gastric GIST and observed that patients 
only developed metastasis in 2–3 % tumors with <10 cm 
and <5 mitosis/50 HPF, compared with 68 % of those who 
presented >10 cm and >5 mitosis/50 HPF [10]. A second 
series including 906 patients with <10 cm and <5 mito-
sis/50 HPF tumor located in the jejunum and ileum, pre-
sented recurrence in 24 % compared to 90 % which pre-
sented >10 cm and >5 mitosis/50 HPF tumor.
Based on this data, these same authors put forward a new 
risk index (AFIP/Miettinen) that includes anatomic site 
Table 2  Risk groups for gastrointestinal stromal tumors according to 
Fletcher et al
*
 Size takes into account the maximum dimension. Variation is 
accepted with the measurement of tumors before or after fixation and 
the existing differences among observers
**
 50 HPF represent between 10 and 12 mm2 in current optical den-
sity. Ideally, the mitotic index should be expressed according to the 
surface to be examined based on the power field magnification (HPF)
Size* Mitotic index  
(50 HPF)**
Very low-risk <2 cm ≤5 mitosis
Low-risk 2–5 cm ≤5 mitosis
Intermediate-risk ≤5 cm 6–10 mitosis
5–10 cm 5 mitosis
High-risk >5 cm >5 mitosis
>10 cm Any number of mitosis
Any size >10 mitosis
Fig. 1  Relapse-free survival analysis according to Fletcher’s risk 
groups in 162 patients registered in GEIS
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[23]. This classification better reflects the high-risk popu-
lation than the Fletcher index (Table 3; Fig. 2), especially 
between the intermediate and low-risk groups. The risk of 
gastric cancer relapse varies from 2 % in tumors with <5 
mitosis per 50 HPF to 90 % in gastrointestinal tract GIST 
with tumors more than <10 cm and <5 mitosis/50 HPF. The 
casuistry of GEIS group has shown that the Miettinen’s 
classification exhibited statistical significance for discrimi-
nating low, intermediate and high-risk groups. This was not 
the case when the Fletcher classification was used [29].
The main differences between both classification sys-
tems lies in patients with gastric GIST, larger than 10 cm 
but with <5 mitosis per HPF. Using Fletcher’s classifi-
cation, the latter would be in the high-risk group with a 
recurrence-free survival (RFS) of 50 % at 5 years. Never-
theless, they would fall within the intermediate-risk cate-
gory with a RFS of 80 % according to the Miettinen group 
classification.
On the other end of the spectrum we find GIST tumors 
with extragastric location of <5 cm and more than 5 mitosis 
per HPF. According to Fletcher’s classification, they would 
fall within the intermediate group with a RFS probability 
of 85 % versus being in the high-risk group with 45 % RFS 
in the Miettinen group classification. It is important to note 
that Miettinen considered a total area 5 mm2 in 50 fields 
HPF characterized by the use of different optical compo-
nents, while in practice 50 HPF typically corresponds to a 
total area of 10 mm2. Therefore, if we use Miettinen’s risk 
classification, we should also make the correction of divid-
ing the number of mitosis by half including the current 
optical elements by 50 HPF.
Other succeeding risk classifications such as the Ameri-
can Joint Committee on Cancer (TNM) [56] or the nom-
ogram [57] for the individual risk assessment show some 
differences such as the anecdotal evidence of ganglionic 
extension or the selection bias that encumber studies in 
some large centers and magnify the likelihood of relapse.
Joensuu H. recently introduced a capsule rupture clas-
sification known as modified NIH that simplifies the site 
classification (gastric/non-gastric) but at the same time 
renders heat maps to be more complex as categorization of 
continuous variables is not used [58].
The NCCN [59] and ESMO [40] guidelines tend to favor 
Miettinen’s classification when capsular rupture is consid-
ered comparable to peritoneal dissemination.
A further problem posed, at least theoretically, is regard-
ing adjuvant imatinib clinical trials designed using Fletch-
er’s risk classification. If we were to adopt a more liber-
alized stance on drugs, we would recommend adjuvant 
imatinib treatment for patients with gastric GIST for tumors 
of 10 cm or larger with <5 mitosis/HPF (considered as high 
risk according to Fletcher), when the risk of recurrence is 
65 %. Therefore, the most rational approach should bear in 
mind the most current prognostic information in which the 
high risk of recurrence category is more accurate.
Although GIST tumors are a model for the so-called 
molecular target therapies, molecular prognostic factors 
have not been incorporated in the risk of recurrence clas-
sifications. There is available evidence indicating that the 
type and location of the mutation has an effect on the risk 
of recurrence. Deletions affecting exon 11, codon 557/558 
of the c-KIT gene, have a higher recurrence risk and it will 
occur within the first 3–4 years after surgery [29, 60]. The 
leading role of “critical mutation” has been confirmed in 
recent series [58, 61].
Table 3  Risk groups for gastrointestinal tumors adapted by Miet-
tinen et al
*
 50 HPF represents an area of 5 mm2 in the optical fields used by 
Miettinen
Size Mitotic index (50 
HPF)*
Location
Very low risk 2–5 cm ≤5 mitosis Gastric
Low risk >5 years ≤10 cm ≤5 mitosis Gastric
2–5 cm ≤5 mitosis Intestinal
Intermediate risk >10 cm ≤5 mitosis Gastric
>5 years ≤10 cm ≤5 mitosis Intestinal
2–5 cm >5 mitosis Gastric
High-risk  
intestinal
2–5 cm >5 mitosis Intestinal
>10 cm ≤5 mitosis Intestinal
>5 years ≤10 cm >5 mitosis Gastric
> 10 cm >5 mitosis Gastric
>5 years ≤10 cm >5 mitosis Intestinal
>10 cm >5 mitosis Intestinal
Fig. 2  Disease-free survival analysis according to Fletcher’s risk 
groups in 162 patients registered in GEIS
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Final recommendations
•	 We recommend the use of the risk group classification 
proposed by Miettinen as it is the best at identifying 
low, intermediate and high-risk populations. Spontane-
ous or intraoperative capsule rupture should be consid-
ered as a very poor prognostic factor.
•	 Deletion type of mutations affecting codons 557 and 
558 confers a risk for recurrence regardless of its previ-
ous classification, according to our experience. The risk 
is greatest within the first 30 months after surgery and 
then drops drastically. Nevertheless, results from other 
prospective studies are needed in order to assess the 
value of this variable.
Adjuvant treatment
Imatinib trials overview
Despite the fact that complete resection is feasible in most 
localized GIST cases, there is still a recurrence rate of up 
to 50 % according to some series. The role of imatinib as 
adjuvant treatment to prevent recurrence has therefore been 
assessed in several clinical trials. Evidence derived from 
the large Phase III randomized trials ACOSOG Z9001 [62] 
and SSGX-VIII/AIO [63], has shown a relapse-free survival 
(RFS) benefit with imatinib. Moreover, the SSGX VIII/AIO 
study showed an increase in overall survival (OS) with 3 years 
of imatinib administration over 1 year in high-risk patients 
(in accordance with NIH modifications). Preliminary results 
of the first interim analysis of EORTC 62024/GEIS-10 study 
[64] have recently been communicated in ASCO 2013. This 
phase III trial included intermediate and high-risk patients 
randomized at 2 years with imatinib over observation.
Although the initial end point was OS, it was changed to 
time to imatinib failure (TIF) in 2009 due to the small num-
ber of relapses in the control group. No significant statistical 
differences were found in either arms (OS and TFI) after a 
4.7-year follow-up. Nevertheless, there was an objective ten-
dency to an improved TFI in high-risk patients (in both NIH 
2002 as well as modified NIH classifications). A benefit was 
also observed in RFS as previous reported studies in favor of 
adjuvant treatment with imatinib in high-risk patients.
In view of these results, both NCCN and ESMO guide-
lines as well as consensus of the scientific community, recom-
mend 3 years of adjuvant treatment with imatinib in high-risk 
patients. Adjuvant treatment for low-risk patients is not indi-
cated. However, currently there is not enough scientific evi-
dence to support adjuvant treatment with imatinib in interme-
diate-risk patients. Based on these considerations, for uncertain 
cases, it is important to carry out an assessment of risk of recur-
rence and properly classify them by using modified classifica-
tion tools (modified Miettinen classification of Joensuu H).
There are still many unclear areas concerning dura-
tion of adjuvant treatment and whether more than 3 years 
of treatment would increase benefit in patients at higher 
risk. Studies like PERSIST-5 may shed some light on this 
issue. Moreover, another aspect that needs to be clarified is 
whether relapse is actually avoided or just delayed, given 
the relapses observed in SSGX-VIII/AIO following adju-
vant treatment interruption at 6–12 months in both arms 
[63].
Special cases
•	 Capsule break: These are generally accepted as dissemi-
nated patients given that 100 % will relapse, at least on 
a peritoneal level. Therefore, imatinib administration is 
recommended as advanced disease setting.
•	 Specific genotypes: Adjuvant imatinib is not recom-
mended in patients with D842 V PDGFRα mutation 
given its known resistance to it. There is no consen-
sus regarding the benefit of a daily dose of 400 mg of 
imatinib for carriers of an exon 9 mutation in the KIT 
gene. The efficacy of a daily dose of 800 mg of imatinib 
was extrapolated from the evidence of disseminated 
disease. Nonetheless, this scenario has not been proven 
in clinical trials and therefore has not been approved 
for adjuvant treatment. Survival in patients with wild 
type does not seem to increase with the use of adju-
vant imatinib, and thus, there is still controversy over 
imatinib administration and each case must be consid-
ered individually.
•	 Patients with R1 surgery: There is no evidence confirm-
ing the benefit of adjuvant imatinib in low-risk patients 
with affected microscopic margins. Surgical reexcision 
could be considered for these cases (see surgical section).
Final recommendations
•	 High-risk patients: 3 years of adjuvant treatment with 
imatinib is recommended.
•	 Low-risk patients: adjuvant treatment is not indicated.
•	 Intermediate-risk patients: currently, there is not enough 
scientific evidence to support adjuvant treatment with 
imatinib. For uncertain cases, it is important to carry out 
an assessment of risk of recurrence and properly clas-
sify them by using modified classification tools (modi-
fied Miettinen classification of Joensuu H).
Advanced disease
Treatment of unresectable or metastatic disease
Dose and efficacy of imatinib treatment Gastrointestinal 
stromal tumors have been a paradigmatic example of chemo-
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resistant tumors with <5 % of responses and 14 months as the 
median of survival reported in the literature. Imatinib mesylate 
(STI571, Gleevec™, Novartis Pharmaceuticals, Basel, Swit-
zerland) is a selective tyrosine kinase inhibitor (TKI), whose 
targets include ABL, BCR-ABL, KIT and PDGFR and con-
stitutes as a very effective agent for the treatment of clinically 
advanced, metastatic or surgically unresectable GIST [65, 66].
The standard dose of imatinib of 400 mg/m2 per day 
was established from two different randomized phase III 
trials in metastatic GIST with positive immunostaining for 
kit (EORTC-ISG-AGITG y NASG-S0033). In both trials, 
daily doses of 400 versus 800 mg were compared without 
any survival difference and with a more favorable toxicity 
profile for lower doses. The clinical benefit rates (CR, PR 
and SD) for 400 and 800 mg were 90 and 88 %, respec-
tively, in NASG-S0033 study. These rates were 91 and 
87 %, respectively, in EORTC-ISG-AGITG study. Further-
more, there was statistically significant difference, in terms 
of progression-free survival (PFS), favoring 800 mg dose in 
an European trial: progression-free rate at 2 years 52 ver-
sus 44 % (HR 0.78) [67, 68]. In a meta-analysis, analyzing 
1,640 patients enrolled in the mentioned trials, a slight but 
still significantly advantage was found in terms of PFS for 
the high-dose arm [48]. Nevertheless, no survival advan-
tage was detected and thus the standard dose, as for general 
recommendation, is 400 mg daily.
Predictive value of genotype for imatinib efficacy Interest-
ingly, one of the notable features of the clinical studies of 
imatinib for GIST treatment is the consistent observation 
that defined subsets of GIST according to their mutational 
status have different outcomes during treatment and there-
fore should be considered in devising treatment strategies.
Responses to imatinib depend on the functional domain 
affected [69]. Table 4 lists the correlation between tumor 
genotype and objective response (both complete and partial 
responses) in four trials (phase I–III). On the basis of 768 
genotyped GIST, the objective response rates for KIT exon 
11, exon 9 mutants and GIST WT are 72, 38 and 28 %, 
respectively [46, 70, 71]. Likewise, the probabilities of pri-
mary resistance to imatinib for KIT exon 11, KIT exon 9 and 
WT GIST are 5, 16 and 23 %, respectively (Table 4). An even 
more striking observation is that KIT and PDGFRA muta-
tional status correlates with time to progression (TTP) and 
overall survival (OS), with superior survival seen for patients 
with GIST carrying an exon 11 KIT mutation. For example, in 
the American phase III trial, the median TTP for patients with 
GIST harboring KIT exon 11, KIT exon 9 and WT was 25, 
17 and 12, 8 months, respectively. A similar OS benefit was 
seen for patients with KIT exon 11 mutations (60 months) 
compared with those observed for KIT exon 9 (38 months) 
or WT (49 months) genotypes. Comparable results regarding 
TTP, OS and KIT mutational status were also observed in the 
European/Australasian phase III trial [46].
On the other hand, the meta-analysis also confirmed the 
observations previously reported in the European/Australa-
sian trial, and therefore, it was concluded that KIT exon 9 
mutations constituted a dose-dependent predictive fac-
tor for imatinib treatment identifying patients with a better 
response to high doses of imatinib (400 mg twice daily). 
Consequently, the estimated risk of progression for patients 
with KIT exon 9 mutations was drastically reduced (42 %; 
p = 0.0017) in the 800-mg/day arm compared with the 400-
mg/day dose of imatinib. In the same direction, the risk of 
death was also reduced in a 31 % in this subgroup of patients.
Only small numbers of patients with GIST harboring 
PDGFRA mutations were included in the original phase 
I–III trials. On the basis of in vitro data, the most com-
mon PDGFRA mutation in GIST, D842 V, is fully resistant 
to the effects of imatinib [33]. Among the patients whose 
GIST harbored a PDGFRA D842 V mutation in the Ameri-
can phase III trial, there were no objective responses and 
stable disease was observed for a few months in some of 
the patients. From in vitro experiments, dasatinib showed 
activity in GIST cell lines with this specific mutation [72], 
somewhat recently confirmed in the clinical setting [73].
Table 4  Relationship between 
KIT mutational status, response 
rate and outcome on imatinib 
therapy
a
 Defined as complete or partial 
response by SWOG (B2222) 
or RECIST criteria (all other 
trials); excluded non-evaluable 
patients
b
 Statistical difference between 


















% (n) % (n) % (n) % (n) % (n)
Objective responsea
KIT exon 11 83 (24) 83b (85) 70b (248) 67b (211) 71 (568)
KIT exon 9 25 (4) 48 (23) 35 (58) 40 (25) 38 (110)
No mutation 33 (6) 0 (9) 25 (52) 39 (33) 28 (100)
Progressive disease
KIT exon 11 4 % 5 % 3 % 8 % 5 %
KIT exon 9 0 % 17 % 17 % 16 % 16 %
No mutation 33 % 56 % 19 % 21 % 23 %
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Thus, taking together the previous information, there is a 
consensus in the following recommendations:
•	 Genotype is mandatory for treating advanced/metastatic 
GIST patients. Evidence II, A.
•	 Imatinib 400 mg/day is the recommended dose in first 
line in advanced/metastatic GIST. Evidence I, A.
•	 In exon 9 mutants, imatinib 800 mg/day is the recom-
mended dose. Evidence III, A.
•	 In PDGFRA/KIT WT GIST is not clear enough that 
imatinib should be the standard.
•	 In imatinib-resistant D842 V mutant, alternative treat-
ments other than imatinib could be advised (i.e., dasat-
inib). Evidence IV, B.
Practical issues on imatinib as first line in GIST 1. H ow 
long should the therapy last? The BFR14 trial, which 
randomized patients with nonprogressive GIST to con-
tinuation versus interruption of imatinib after 1, 3, or 
5 years of treatment, showed that treatment interrup-
tion was associated with a high risk of progression 
even in patients with a complete response [13]. Inter-
estingly, although imatinib rechallenge could control 
the disease in most patients, the quality of the tumor 
response rarely reached that before treatment inter-
ruption. Consequently, in patients with metastatic or 
unresectable GIST, imatinib should be continued until 
disease progression even when metastatic lesions have 
been previously surgically excised or until unaccepta-
ble toxicity. Evidence II, B.
2. Compliance. Although imatinib is usually a well-toler-
ated drug with as few as 2 % of grade III–IV adverse 
events, the long duration of therapy and persistent 
grade I–II side effects could impact in treatment com-
pliance and consequently in disease outcome. There-
fore, a good education of patients regarding the impor-
tance of compliance and potential interactions with 
other drugs or foods as well a proper and prompt man-
agement of side effects is crucial.
3. Imatinib plasma levels. Although it remains to be dem-
onstrated in a prospective setting, retrospective data 
suggest that low plasma levels at steady state are asso-
ciated with a worse outcome. So, the median time to 
progression was 11.3 months for patients with imatinib 
plasma levels <1, 11 ng/mL compared to more than 
30 months for patients with plasma levels above that 
threshold [14]. Plasma levels could be especially use-
ful in case of suspected bad compliance as the cause 
of tumor progression, in patients at risk of potentially 
important interactions with other concomitant drugs or 
unexpected toxicities. Evidence IV, B.
4. Rechallenge of imatinib after adjuvant treatment. For 
patients recurring during adjuvant treatment, second-
line treatments including imatinib 800 mg/day should 
be discussed. For those patients relapsing with meta-
static or unresectable disease after imatinib interrup-
tion, although no direct prospective evidence is avail-
able, based on the data from the previously mentioned 
BRF14 trial, the general recommendation is that 
imatinib should be reintroduced at the same dose as 
recommended for first line. Evidence II, B.
Treatment for patients with disease progression 
following imatinib failure
The first step to undertake when dealing with advanced GIST 
patients, who have progressed despite imatinib treatment, is 
to ensure treatment adherence and check for drug interac-
tions that might decrease efficacy. Consideration may also be 
given to determine plasma imatinib concentrations, to better 
analyze these issues [78]. If there is proper treatment compli-
ance, systemic treatment will have to be modified.
Imatinib dose escalation. The first recommended thera-
peutic maneuver consists of increasing the dose of imatinib 
to 800 mg/daily. The decision is based on results of cross-
over to 800 mg after disease progression on 400 mg in 
EORTC phase III trial studies [79] and American Inter-
group (study S0033) [68]. In both cases, the observed 
progression-free rates in patients receiving a higher dos-
age were 30–35 %. The median time to progression was 
3–4 months. However, in one of the studies, 18 % of 
patients remained progression free during 1 year. The inci-
dence of anemia and asthenia increases significantly with 
this dosage; therefore, a strict follow-up is required. Results 
from a retrospective EORTC trial indicated that 800 mg 
dose is more effective than 400 mg in patients who have 
KIT exon 9 mutations [46]. These data were published 
recently in a meta-analysis including 722 patients [48].
Sunitinib is a multitargeted or selective TKI active inhib-
itor that is active against alpha-type and beta-type PDGFR 
and VEGFR receptors. Results of a randomized phase III 
trial versus placebo revealed a prolongation of the time to 
progression from 1.5 to 6.3 months in patients with GIST 
who progressed despite imatinib treatment [80]. Accord-
ingly, it has been approved by the EMA and FDA as treat-
ment for GIST resistant to imatinib therapy and for those 
who do not tolerate it. The recommended dose is 50 mg 
orally once a day during 4 weeks followed by a 2-week rest 
period, although an uninterrupted daily dose of 37, 5 mg 
is a valid alternative [81]. The most common side effects 
were asthenia, skin toxicity, diarrhea, hypertension and 
hypothyroidism. A prospective study showed an increased 
drug efficacy in patients with wild-type KIT GIST or muta-
tions in exon 9 and 11 [49]. Likewise, patients who ben-
efited most from sunitinib treatment were those with sec-
ondary KIT mutations in exon 13 and 14 compared to those 
with exon 17 and 18 mutations.
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Regorafenib is a second generation TK inhibitor tar-
geting KIT, RET, BRAF, VEGFR, PDGFR and FGFR. A 
median PFS of 4.8 months with imatinib, sunitinib and 
regorafenib versus 0.9 months with placebo was observed 
in a randomized trial for patients with refractory GIST. 
The most frequent side effects were high-blood pressure, 
hand-foot syndrome and diarrhea [82]. The only available 
preliminary data showed a correlation between genotype 
and regorafenib sensitivity, suggesting significant activity 
against KIT exon 11 mutations and those found in the KIT-
activating mutations loops as well as some forms of KIT 
wild type. Regorafenib has the FDA approval and is cur-
rently undergoing assessment by the EMA as treatment for 
advanced GIST after failure of imatinib and sunitinib.
The available treatment options following imatinib, 
sunitinib and regorafenib administration (the latter follow-
ing approval of regulatory authorities) are still in the exper-
imental phase. The first recommendation is to offer these 
patients the opportunity to participate in clinical trials con-
ducted under an investigational new drug. If this is not pos-
sible, an individual treatment can be scheduled for selected 
patients with other drugs such as:
Nilotinib is a second generation TK inhibitor active in 
chronic myeloid leukemia and with the inhibitory effect of 
KIT and PDGF. Preliminary results of a phase III trial com-
paring nilotinib with imatinib, sunitinib or supportive care 
in resistant GIST patients whose disease had progressed 
to imatinib and sunitinib did not show differences in PFS 
and OS treatment groups. On the other hand, significant 
differences in overall survival were noted when the analy-
ses were limited to those who received nilotinib as strictly 
third-line treatment (excluding those who had received 
additional therapy) [83].
Sorafenib is a VEGFR, KIT, PDGR and BRAF inhibi-
tor. Preliminary results of a phase II trial showed activity 
in imatinib-resistant and sunitinib-resistant patients with 
acceptable tolerance. This could be an alternative until 
regorafenib becomes available [84].
Imatinib and doxorubicin combination: Promising activ-
ity was been observed in a GEIS group study with doxoru-
bicin dose of 20 mg/m2/once a week, which could be par-
ticularly suitable for patients with wild-type GIST [85].
Response evaluation
An abdominal and pelvic CT with contrast and image 
acquisitions of the arterial and portal phases allows iden-
tification of hypervascular hepatic lesions that would 
otherwise go unnoticed and become evident when they 
become hypodense with treatment. Choi criteria [74] com-
bine changes in both size (RECIST) and density measures 
(Hounsfield Units: HU). Responses can mimic progression 
due to the increasing size of some lesions that can only be 
interpreted if HU are considered [75]. On the contrary, a 
CT scan without endovenous contrast detects hemorrhage 
or intratumoral calcification.
Other techniques such as MRI are strictly limited to hepatic 
studies, complex locations such as the rectum [76] and aller-
gic reactions to iodine contrast, since evaluation of HU is not 
feasible. PET is reserved for inconclusive cases by other tech-
niques such as CT or MRI or the early assessment of response 
to imatinib [77]. However, PET is useful for early detection of 
responses, mandatory in some neo-adjuvant indications.
Both RECIST 1.1 and Choi [74] criteria must be taken 
into account to avoid confounding it with pseudoprogres-
sion due to myxoid degeneration or intratumoral hemor-
rhage (Table 5).
Follow‑up of patient diagnosed with gist
An abdomen and pelvic CT with contrast and image acqui-
sitions of the arterial and portal phases is the method of 
choice for initial diagnosis and follow-up for GIST. Due to 
low metastatic frequency of pulmonary metastases (2 %) 
[86], thoracic imaging study is only indicated based on 
clinical suspicion. There are no studies analyzing the effi-
cacy of different follow-up strategies. Follow-up will be 
stratified based on risk, size, number of mitosis and loca-
tion according to the Miettinen classification [9].
Other techniques such as MRI are strictly limited to 
hepatic studies, complex locations such as the rectum and 
allergic reactions to iodine contrast given that evaluation of 
Hounsfield units is not feasible. PET is reserved for incon-
clusive cases by other techniques such as CT or MRI or the 
early assessment of response to imatinib [77].
Localized resectable disease
Follow-up after resection according to risk group:
Very low risk: Routine follow-up is not indicated due to 
the low-risk of relapse- even if it is not null.
Low risk: Follow-up can be carried out every 6 months 
at diagnosis up to the fifth year.
Intermediate high risk: Patients receiving adjuvant imatinib 
treatment require regular monitoring with clinical analysis 
every 3 months to control drug tolerance. A follow-up CT scan 
should be done every 3–6 months during adjuvant treatment. 
The highest risk of recurrence takes place in the first 2 years. 
After this period, a CT scan should be performed every 
3–6 months up to the fifth year and annually up to 10 years.
Localized unresectable or metastatic disease
Follow-up should be conducted every 3 months since the 
beginning and can be prolonged up to every 6 months if 
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response is obtained, especially if response remains beyond 
a 5-year period. Both RECIST 1.1 and Choi [74] criteria 
must be taken into account to avoid confounding it with 
pseudoprogression due to myxoid degeneration or intratu-
moral hemorrhage as previously described.
Special cases
Neoadjuvant and induction therapy
Systemic induction therapy has the aim of facilitating sur-
gery through tumor shrinkage, whereas systemic neoadju-
vant therapy targets survival advantage [87].
In locally advanced and unresectable GIST, there are 
few cases that would eventually become resectable after 
induction treatment with imatinib [88]. However, for those 
locally and resectable GIST for which a mutilating surgery 
is planned, a cytoreductive treatment with imatinib should 
be attempted. Thus, in gastric GIST to avoid subtotal gas-
trectomy, duodenal GIST near the ampulla of Vater or rec-
tal GIST to avoid abdominoperineal amputation.
Early assessment of response is needed to minimize risks 
since a delay could further hamper surgery after an unsuc-
cessful imatinib treatment. Mutational analysis should be 
mandatory due to the robust genotype predictive biomarker 
(IIb). Hence, exon 9 mutants would require 800 mg/day of 
imatinib; D842 V mutants no induction treatment would be 
active and for those KIT/PDGFRA wild type, is doubtful 
that imatinib could be active enough. A CT scan can be of 
some usefulness for assessing early response, but the use 
of PET scan after induction therapy seems more advanta-
geous given its ability to verify the efficacy of the treatment 
within a very short time [89].
The recommended duration of preoperatory treatment 
cannot be based on objective criteria. However, it is esti-
mated that surgery could be performed within 6–12 months 
after starting imatinib, since maximal response and mini-
mal risk of secondary resistance is expected in this time 
interval.
Final recommendations
1. There is a lack of published evidence regarding neoad-
juvant treatment in operable GIST and therefore should 
not be used outside clinical trials.
2. Induction treatment could be recommended in indi-
vidual basis with the aim of offering a less mutilating/
function sparing surgery.
Small GIST<2 cm
Many small GIST, <2 cm, are incidental findings during 
surgeries carried out for a number of other reasons. A small 
GIST found accidentally in a surgical specimen does not 
require any additional therapeutic procedure.
In those uncommon cases of small GIST diagnosed 
before surgery, the excision is not clear enough and a shared 
decision-making process with the patient should be offered.
Anyway, the mitotic index of those tumors should be 
taken into account, although the incidence of small size and 
high mitotic index is very low according the literature.
Focal progression
There is a well-documented type of secondary resistance to 
imatinib called nodule within mass. This is a focal disease 
progression, while most of the tumor burden is still under 
Table 5  Response evaluation criteria
FDG fluorodeoxyglucose, PET positron emission tomography, SUV standardized uptake volume, HU Hounsfield units
RECIST PET Choi criteria
Complete response (CR) All lesions must disappear Lack of FDG uptake All lesions must disappear
Unable to distinguish it from sur-
rounding tissue
No new lesions
Partial response (PR) Decreasing size 30 % of  
sum of target lesions
Decreasing size 15–25 % of SUV  
after 1 cycle and more than 25 % 
after subsequent cycles
Decreasing size >10 % or decreasing 
density ≥15 % HU
Stable disease (SD) Between PR and PD <25 % increase or SUV 
decreases <15 %
Does not fufil CR, PR or PD criteria
No symptom deterioration due to tumor 
progression
Progressive disease (PD) Target lesions increase >20 % SUV increases >25 % or new  
lesion uptake
Size increases >10 % without density 
decreasing
New intratumoral nodules
Size or tissue part of hypodense lesion 
increases
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control. For these cases, maintenance of systemic treatment 
(generally imatinib) as well as applying local measures, 
can keep the patient free of progression for over a year in 
one-third of cases (xii). It is the treatment of choice over 
second-line systemic treatments.
The most common local treatments are surgery, radioa-
blation and arterial embolization. In the absence of con-
trolled trials, the choice of treatment should be based dis-
ease characteristics as well as on an experienced medical 
team.
Final recommendations
•	 Systemic therapy should not be interrupted or replaced 
when progression is limited to a single or only a few 
focal points amenable to local treatment.
•	 Choice treatment for focal progression is maintenance 
of systemic therapy together with local control tech-
niques appropriate for each case.
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